Pressure BioSciences Faces Delisting from Nasdaq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences has been told by Nasdaq that it is once again in danger of having its stock delisted, the company disclosed in a document filed with the US Securities and Exchange Commission on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.